Tag:
Clinical Data
Latest Headlines
Latest Headlines
New Zelboraf data shows big survival boost
Roche's ( $RHHBY ) new melanoma drug Zelboraf apparently works even better than researchers suspected.
ESC backs AZ drug over Plavix on mortality benefit
AstraZeneca's ( $AZN ) new bloodthinner Brilinta--sold as Brilique in Europe--got a thumbs up from the European Society of Cardiology. In revised treatment guidelines, the ESC recommended Brilique over
FDA highlights new tech to monitor trials
The FDA is encouraging drug developers to turn to new technology to help them monitor clinical trial work without resorting to frequent site visits, according to a report in Outsourcing-Pharma. In a
Billionaire biotech investor touts his next Big Thing
Randal J. Kirk made $1.2 billion when he sold New River and its attention deficit disorder drug to Shire. He stands to add to that fortune now that another biotech he's backed, Clinical Data, is
Forest Labs swallows Clinical Data pill in $1.2B buyout
Just weeks after Clinical Data ( $CLDA ) won a surprising approval for a new antidepressant, Forest Laboratories has swept in to buy the biotech for $1.2 billion, paying $30 a share plus a CVR that
Clinical Data hires reps for Viibryd launch
Now that Clinical Data has an FDA approval in hand, it's gearing up to grab a piece of the $12 billion antidepressant market. The company is hiring sales reps and rolling out a marketing campaign to
Clinical Data wins FDA OK for new antidepressant
Clinical Data ($CLDA) has elbowed its way into the crowded market for antidepressants, winning FDA approval for a new drug it in-licensed from Merck KGaA. Regulators signed off on three doses of
Amgen: Denosumab demonstrates superiority over Zometa
Amgen's denosumab was more effective than Novartis' Zometa (zoledronic acid) in delaying fractures in men with advanced prostate cancer, according to results of 1,901-patient Phase III trial. In
Merck KGaA pulls ahead in hot oral MS drug race
Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential as a new therapy for multiple sclerosis. Patients taking a short
Clinical Data, CombinatoRx ink $257M cancer drug deal
Working to rebuild itself in the wake of last fall's clinical trial pratfall, CombinatoRx has agreed to pay up to $257 million for the licensing rights to Clinical Data's multiple myeloma treatment,
